MedRhythms Announces Key Publications Confirming Efficacy, Safety, and Usability of InTandem™ for Chronic Stroke Walking Impairment
08 Feb 2024
Clinical Result
Multi-center randomized controlled trial achieved primary endpoint: Use of InTandem resulted in a clinically-meaningful and statistically-significant increase in walking speed.
Participants randomized to InTandem were three times more likely to be responders as compared to an active control.
Safe and effective home-use was confirmed in a summative usability study.
PORTLAND, Maine, Feb. 8, 2024 /PRNewswire/ -- MedRhythms announced today publication of two studies validating the efficacy, safety, and usability of InTandem™, a FDA-authorized, prescription-only neurorehabilitation system for home use to improve walking and ambulation in adults with chronic stroke. Results of the multi-site randomized controlled trial demonstrated the clinical benefits and safety of InTandem, and were published in Nature Communications. The summative usability study, results of which were published in JMIR Rehabilitation and Assistive Technologies, confirmed the safe and effective use of InTandem by people with chronic stroke in the home environment.
Preview
Source: PRNewswire
InTandem™ includes shoe-worn sensors, a headset, and a touchscreen control unit.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.